… demand for its weight loss drug cemented its position … in midday trading. Weight-loss drugs are in high demand … weight loss pill, which could come as soon as April. Novo launched a weight loss pill … and potentially more effective weight-loss drugs in a range …

… turning to Lilly’s oral weight-loss pill, orforglipron, which is under FDA …

… fight to break into the weight loss drug market. For one, they’re … more weight than any other weight-loss drug during a late-stage trial …

… represents 25% growth. Revenues From Weight Loss Drugs Novo Nordisk’s Ozempic sales … products, heart disease medicines, and weight loss drugs. Whereas Eli Lilly's …

Dive Brief: Eli Lilly shares jumped early Wednesday after the company reported better-than-expected fourth-quarter revenue and shared higher forecasts for 2026, buoyed by its obesity and diabetes medicines. Fourth-quarter revenue soared 43% to $19.3 …

The company said fourth-quarter revenue rose 43% to $19.3bn, driven by volume growth from both Mounjaro and Zepbound. Earnings per share were 51% higher at $7.39 on a reported basis, and 42% higher at $7.54 on a non-GAAP basis. In Q4, worldwide Mounjaro …

… offset by lower realized prices. Weight Loss Drugs Key Products revenue grew to …